GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:GNMK
- CUSIP: N/A
- Web: www.genmarkdx.com
Capitalization:- Market Cap: $569.28 million
- Outstanding Shares: 47,087,000
Average Prices:- 50 Day Moving Avg: $12.12
- 200 Day Moving Avg: $12.34
- 52 Week Range: $8.03 - $13.67
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -20.15
- P/E Growth: 10.13
Sales & Book Value:- Annual Revenue: $50.75 million
- Price / Sales: 11.22
- Book Value: $0.57 per share
- Price / Book: 21.21
Profitability:- EBIDTA: ($45,600,000.00)
- Net Margins: -101.61%
- Return on Equity: -146.00%
- Return on Assets: -70.45%
Debt:- Debt-to-Equity Ratio: 0.45%
- Current Ratio: 2.00%
- Quick Ratio: 1.57%
Misc:- Average Volume: 341,536 shs.
- Beta: 1.04
- Short Ratio: 12.42
Frequently Asked Questions for GenMark Diagnostics (NASDAQ:GNMK)
What is GenMark Diagnostics' stock symbol?
GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."
How were GenMark Diagnostics' earnings last quarter?
GenMark Diagnostics, Inc. (NASDAQ:GNMK) released its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.02. The firm earned $12.54 million during the quarter, compared to analysts' expectations of $12.55 million. GenMark Diagnostics had a negative return on equity of 146.00% and a negative net margin of 101.61%. View GenMark Diagnostics' Earnings History.
Where is GenMark Diagnostics' stock going? Where will GenMark Diagnostics' stock price be in 2017?
5 brokers have issued 12 month price objectives for GenMark Diagnostics' shares. Their forecasts range from $13.00 to $17.00. On average, they expect GenMark Diagnostics' share price to reach $16.20 in the next twelve months. View Analyst Ratings for GenMark Diagnostics.
What are analysts saying about GenMark Diagnostics stock?
Here are some recent quotes from research analysts about GenMark Diagnostics stock:
- 1. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (5/3/2017)
- 2. Needham & Company LLC analysts commented, "GNMK's 4Q16 revenue was consistent with its 1/10/17 preannouncement while its EPS was in line with consensus. Management provided initial 2017 revenue guidance that bracketed consensus. As previously disclosed on 1/10/17, GNMK ended 2016 with more than 55 customer agreements for over 85 ePlex instruments which seems to bode well for ePlex demand. GNMK announced that it submitted its ePlex 510(k) to the FDA on 12/22/16 and noted that it expects to obtain CE Marks for its three blood culture panels in 2Q17. With the European ePlex launch underway and the U.S. ePlex launch set for mid-2017, we reiterate our Buy rating since we expect ePlex to drive a significant acceleration in revenue growth." (3/1/2017)
Who are some of GenMark Diagnostics' key competitors?
Some companies that are related to GenMark Diagnostics include Mazor Robotics (MZOR), Luminex Corporation (LMNX), LeMaitre Vascular (LMAT), Accuray Incorporated (ARAY), Corindus Vascular Robotics (CVRS), Pacific Biosciences of California (PACB), ViewRay (VRAY), Cytosorbents Corporation (CTSO), Alliance HealthCare Services (AIQ), Viveve Medical (VIVE), Fulgent Genetic (FLGT), IRIDEX Corporation (IRIX), Cogentix Medical (CGNT), EDAP TMS S.A. (EDAP), Neovasc Inc (US) (NVCN), Harvard Bioscience (HBIO), Digirad Corporation (DRAD) and Biolase (BIOL).
Who are GenMark Diagnostics' key executives?
GenMark Diagnostics' management team includes the folowing people:
- James Charles Fox Ph.D., Independent Chairman of the Board
- Hany Massarany, President, Chief Executive Officer, Director
- Scott Mendel, Chief Financial Officer
- Jon Faiz Kayyem Ph.D., Senior Vice President - Research and Development, Chief Scientific Officer
- Eric Stier, Senior Vice President, General Counsel, Secretary
- Jennifer Anne Williams, Senior Vice President - Human Resources
- Michael W Gleeson, Senior Vice President, North American Commercial Operations
- Michael S Kagnoff, Director
- Daryl Jay Faulkner, Independent Director
- Lisa M. Giles, Independent Director
Who owns GenMark Diagnostics stock?
GenMark Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Quantitative Systematic Strategies LLC (0.03%). Company insiders that own GenMark Diagnostics stock include Daryl Faulkner, Eric Stier, Hany Massarany, Ingo Chakravarty, Jennifer Anne Williams, Jon Faiz Kayyem, Lisa M Giles, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.
Who bought GenMark Diagnostics stock? Who is buying GenMark Diagnostics stock?
GenMark Diagnostics' stock was bought by a variety of institutional investors in the last quarter, including Quantitative Systematic Strategies LLC. Company insiders that have bought GenMark Diagnostics stock in the last two years include Daryl Faulkner, Lisa M Giles, Michael Kagnoff and Scott Mendel. View Insider Buying and Selling for GenMark Diagnostics.
How do I buy GenMark Diagnostics stock?
Shares of GenMark Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GenMark Diagnostics' stock price today?
One share of GenMark Diagnostics stock can currently be purchased for approximately $12.09.
MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for GenMark Diagnostics (NASDAQ:GNMK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $16.20 (34.00% upside) |
Analysts' Ratings History for GenMark Diagnostics (NASDAQ:GNMK)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/13/2017 | Needham & Company LLC | Boost Price Target | Buy -> Buy | $16.00 -> $17.00 | High |  |
| 6/12/2017 | Canaccord Genuity | Reiterated Rating | Buy | $17.00 | Medium | |
| 5/17/2017 | BTIG Research | Reiterated Rating | Buy | $17.00 | Medium | |
| 9/16/2016 | Cowen and Company | Upgrade | Market Perform -> Outperform | $17.00 | N/A | |
| 7/29/2016 | J P Morgan Chase & Co | Boost Price Target | Overweight | $10.00 -> $13.00 | N/A | |
| 2/26/2016 | Raymond James Financial, Inc. | Lower Price Target | Outperform | $9.00 -> $7.25 | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for GenMark Diagnostics (NASDAQ:GNMK)Earnings History by Quarter for GenMark Diagnostics (NASDAQ GNMK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/2/2017 | Q1 2017 | ($0.28) | ($0.30) | $12.55 million | $12.54 million | View | Listen | |
| 2/28/2017 | Q416 | ($0.27) | ($0.27) | $15.03 million | $14.90 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.31) | ($0.27) | $10.36 million | $10.80 million | View | N/A | |
| 7/28/2016 | Q216 | ($0.33) | ($0.30) | $9.62 million | $12.50 million | View | Listen | |
| 5/3/2016 | Q116 | ($0.29) | ($0.30) | $10.67 million | $11.06 million | View | N/A | |
| 2/23/2016 | Q415 | ($0.27) | ($0.21) | $12.34 million | $13.20 million | View | Listen | |
| 10/27/2015 | Q315 | ($0.31) | ($0.27) | $8.24 million | $8.80 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.31) | ($0.29) | $7.59 million | $7.65 million | View | N/A | |
| 5/5/2015 | Q115 | ($0.24) | ($0.24) | $10.10 million | $10.10 million | View | N/A | |
| 2/24/2015 | Q414 | ($0.28) | ($0.21) | $9.83 million | $9.83 million | View | N/A | |
| 10/30/2014 | Q314 | ($0.32) | ($0.23) | $5.80 million | $6.30 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.29) | ($0.27) | $4.79 million | $6.55 million | View | N/A | |
| 5/6/2014 | Q114 | ($0.25) | ($0.21) | $6.40 million | $7.91 million | View | N/A | |
| 3/11/2014 | Q413 | ($0.22) | ($0.21) | $6.06 million | $6.45 million | View | N/A | |
| 11/12/2013 | Q313 | ($0.27) | ($0.24) | $4.60 million | $4.64 million | View | Listen | |
| 8/7/2013 | Q2 2013 | ($0.26) | ($0.25) | $5.05 million | $5.20 million | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.17) | ($0.13) | $9.53 million | $11.10 million | View | N/A | |
| 11/10/2011 | | ($0.32) | ($0.31) | | | View | N/A | |
| 8/5/2011 | | ($0.45) | ($0.39) | | | View | N/A | |
| 5/9/2011 | | ($0.49) | ($0.56) | | | View | N/A | |
| 3/3/2011 | | ($0.52) | ($0.30) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for GenMark Diagnostics (NASDAQ:GNMK)Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-0.60 EPS
Dividend History for GenMark Diagnostics (NASDAQ:GNMK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for GenMark Diagnostics (NASDAQ:GNMK)Insider Ownership Percentage: 7.50%
Institutional Ownership Percentage: 92.58%
Insider Trades by Quarter for GenMark Diagnostics (NASDAQ:GNMK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/2/2017 | Michael Gleeson | SVP | Sell | 357 | $12.89 | $4,601.73 | |
| 5/19/2017 | Hany Massarany | Insider | Sell | 8,239 | $12.89 | $106,200.71 | |
| 5/19/2017 | Michael Gleeson | SVP | Sell | 1,916 | $12.89 | $24,697.24 | |
| 5/19/2017 | Scott Mendel | CFO | Sell | 2,135 | $12.89 | $27,520.15 | |
| 5/16/2017 | Scott Mendel | CFO | Sell | 1,268 | $13.43 | $17,029.24 | |
| 5/2/2017 | Eric Stier | SVP | Sell | 362 | $13.34 | $4,829.08 | |
| 5/2/2017 | Hany Massarany | Insider | Sell | 1,571 | $13.34 | $20,957.14 | |
| 5/2/2017 | Scott Mendel | CFO | Sell | 232 | $13.34 | $3,094.88 | |
| 3/3/2017 | Michael Gleeson | SVP | Sell | 353 | $12.29 | $4,338.37 | |
| 2/21/2017 | Hany Massarany | Insider | Sell | 33,537 | $10.08 | $338,052.96 | |
| 2/21/2017 | Jon Faiz Kayyem | SVP | Sell | 5,250 | $10.08 | $52,920.00 | |
| 2/21/2017 | Scott Mendel | CFO | Sell | 8,595 | $10.08 | $86,637.60 | |
| 2/2/2017 | Hany Massarany | Insider | Sell | 1,142 | $11.58 | $13,224.36 | |
| 2/2/2017 | Jennifer Anne Williams | SVP | Sell | 332 | $11.58 | $3,844.56 | |
| 2/2/2017 | Scott Mendel | CFO | Sell | 235 | $11.58 | $2,721.30 | |
| 1/19/2017 | Hany Massarany | Insider | Sell | 27,124 | $12.47 | $338,236.28 | |
| 1/19/2017 | Michael Gleeson | SVP | Sell | 9,569 | $12.47 | $119,325.43 | |
| 1/19/2017 | Scott Mendel | CFO | Sell | 9,098 | $12.47 | $113,452.06 | |
| 12/5/2016 | Jennifer Anne Williams | SVP | Sell | 336 | $11.31 | $3,800.16 | |
| 12/2/2016 | Michael Gleeson | SVP | Sell | 357 | $11.30 | $4,034.10 | |
| 11/22/2016 | Michael Kagnoff | Director | Buy | 2,000 | $11.80 | $23,600.00 | |
| 11/14/2016 | Michael Kagnoff | Director | Buy | 2,000 | $12.50 | $25,000.00 | |
| 11/2/2016 | Hany Massarany | Insider | Sell | 1,148 | $10.30 | $11,824.40 | |
| 11/2/2016 | Michael Gleeson | SVP | Sell | 400 | $10.30 | $4,120.00 | |
| 9/7/2016 | Hany Massarany | Insider | Sell | 1,186 | $8.69 | $10,306.34 | |
| 9/7/2016 | Jennifer Anne Williams | SVP | Sell | 523 | $8.69 | $4,544.87 | |
| 9/2/2016 | Jon Faiz Kayyem | SVP | Sell | 133 | $8.62 | $1,146.46 | |
| 8/29/2016 | Jennifer Anne Williams | SVP | Sell | 24,172 | $8.63 | $208,604.36 | |
| 8/22/2016 | Michael Gleeson | SVP | Sell | 7,500 | $9.00 | $67,500.00 | |
| 8/12/2016 | Lisa M Giles | Director | Buy | 823 | $9.40 | $7,736.20 | |
| 8/2/2016 | Eric Stier | SVP | Sell | 367 | $9.88 | $3,625.96 | |
| 8/2/2016 | Hany Massarany | Insider | Sell | 1,147 | $9.88 | $11,332.36 | |
| 6/7/2016 | Hany Massarany | CEO | Sell | 1,188 | $8.98 | $10,668.24 | |
| 6/7/2016 | Michael Gleeson | SVP | Sell | 868 | $8.80 | $7,638.40 | |
| 6/3/2016 | Ingo Chakravarty | SVP | Sell | 184 | $8.53 | $1,569.52 | |
| 5/9/2016 | Ingo Chakravarty | SVP | Sell | 582 | $5.42 | $3,154.44 | |
| 5/2/2016 | Eric Stier | SVP | Sell | 363 | $5.79 | $2,101.77 | |
| 5/2/2016 | Hany Massarany | CEO | Sell | 1,160 | $5.79 | $6,716.40 | |
| 3/10/2016 | Michael Kagnoff | Director | Buy | 2,500 | $4.90 | $12,250.00 | |
| 3/7/2016 | Hany Massarany | CEO | Sell | 1,193 | $5.76 | $6,871.68 | |
| 3/7/2016 | Michael Gleeson | SVP | Sell | 559 | $5.76 | $3,219.84 | |
| 3/2/2016 | Eric Stier | SVP | Sell | 365 | $4.87 | $1,777.55 | |
| 2/9/2016 | Ingo Chakravarty | SVP | Sell | 697 | $5.04 | $3,512.88 | |
| 2/3/2016 | Hany Massarany | CEO | Sell | 9,173 | $4.99 | $45,773.27 | |
| 2/3/2016 | Michael Gleeson | SVP | Sell | 3,083 | $4.99 | $15,384.17 | |
| 1/21/2016 | Hany Massarany | CEO | Sell | 648 | $6.80 | $4,406.40 | |
| 1/21/2016 | Michael Gleeson | SVP | Sell | 227 | $6.80 | $1,543.60 | |
| 12/8/2015 | Eric Stier | SVP | Sell | 240 | $7.26 | $1,742.40 | |
| 12/8/2015 | Hany Massarany | CEO | Sell | 1,735 | $7.26 | $12,596.10 | |
| 12/3/2015 | Hany Massarany | CEO | Sell | 3,571 | $7.71 | $27,532.41 | |
| 12/3/2015 | Michael Gleeson | SVP | Sell | 1,664 | $7.62 | $12,679.68 | |
| 11/3/2015 | Lisa M Giles | Director | Buy | 4,000 | $6.60 | $26,400.00 | |
| 10/30/2015 | Michael Kagnoff | Director | Buy | 5,000 | $6.70 | $33,500.00 | |
| 10/30/2015 | Scott Mendel | CFO | Buy | 10,000 | $6.47 | $64,700.00 | |
| 10/29/2015 | Daryl Faulkner | Director | Buy | 4,000 | $7.33 | $29,320.00 | |
| 9/15/2015 | Jennifer Anne Williams | SVP | Sell | 14,245 | $9.98 | $142,165.10 | |
| 9/14/2015 | Jennifer Anne Williams | SVP | Sell | 9,245 | $10.00 | $92,450.00 | |
| 9/11/2015 | Hany Massarany | CEO | Sell | 1,683 | $9.64 | $16,224.12 | |
| 9/11/2015 | Jennifer Anne Williams | SVP | Sell | 18,280 | $9.99 | $182,617.20 | |
| 9/4/2015 | Jennifer Anne Williams | SVP | Sell | 1,867 | $9.59 | $17,904.53 | |
| 9/2/2015 | Hany Massarany | CEO | Sell | 3,865 | $9.62 | $37,181.30 | |
| 8/24/2015 | Scott Mendel | CFO | Buy | 10,000 | $9.10 | $91,000.00 | |
| 6/16/2015 | Hany Massarany | CEO | Sell | 1,698 | $9.12 | $15,485.76 | |
| 6/4/2015 | Michael Gleeson | SVP | Sell | 1,595 | $9.55 | $15,232.25 | |
| 6/3/2015 | Hany Massarany | CEO | Sell | 3,486 | $9.47 | $33,012.42 | |
| 4/9/2015 | Hany Massarany | CEO | Sell | 5,942 | $11.52 | $68,451.84 | |
| 3/13/2015 | Jennifer Anne Williams | SVP | Sell | 30,000 | $12.56 | $376,800.00 | |
| 3/11/2015 | Hany Massarany | CEO | Sell | 28,110 | $11.88 | $333,946.80 | |
| 3/11/2015 | Jeffrey Alan Hawkins | SVP | Sell | 6,832 | $12.01 | $82,052.32 | |
| 3/10/2015 | Jennifer Anne Williams | SVP | Sell | 722 | $11.83 | $8,541.26 | |
| 3/10/2015 | Michael Kagnoff | Director | Buy | 5,000 | $11.84 | $59,200.00 | |
| 3/9/2015 | Ingo Chakravarty | SVP | Sell | 3,310 | $12.06 | $39,918.60 | |
| 1/22/2015 | Hany Massarany | CEO | Sell | 5,982 | $12.88 | $77,048.16 | |
| 1/7/2015 | Hany Massarany | CEO | Sell | 4,858 | $13.00 | $63,154.00 | |
| 12/16/2014 | Kevin C Oboyle | Director | Sell | 291 | $12.40 | $3,608.40 | |
| 12/15/2014 | Eric Stier | SVP | Sell | 235 | $12.51 | $2,939.85 | |
| 12/15/2014 | Hany Massarany | CEO | Sell | 1,700 | $12.51 | $21,267.00 | |
| 12/4/2014 | Hany Massarany | CEO | Sell | 3,300 | $12.06 | $39,798.00 | |
| 12/4/2014 | Jeffrey Alan Hawkins | SVP | Sell | 1,350 | $12.06 | $16,281.00 | |
| 10/31/2014 | Jon Faiz Kayyem | SVP | Sell | 6,000 | $11.01 | $66,060.00 | |
| 10/8/2014 | Hany Massarany | CEO | Sell | 5,804 | $9.00 | $52,236.00 | |
| 10/7/2014 | Michael Gleeson | SVP | Sell | 55 | $9.10 | $500.50 | |
| 9/12/2014 | Hany Massarany | CEO | Sell | 1,678 | $9.86 | $16,545.08 | |
| 9/5/2014 | Hany Massarany | CEO | Sell | 3,795 | $10.04 | $38,101.80 | |
| 9/5/2014 | Michael Gleeson | SVP | Sell | 1,833 | $10.04 | $18,403.32 | |
| 8/7/2014 | Michael Gleeson | SVP | Sell | 52 | $11.15 | $579.80 | |
| 7/1/2014 | Jon Faiz Kayyem | SVP | Sell | 6,000 | $13.60 | $81,600.00 | |
| 6/11/2014 | Hany Massarany | CEO | Sell | 1,115 | $11.64 | $12,978.60 | |
| 6/5/2014 | Jon Faiz Kayyem | SVP | Sell | 1,483 | $10.69 | $15,853.27 | |
| 6/3/2014 | Hany Massarany | CEO | Sell | 2,700 | $10.67 | $28,809.00 | |
| 5/29/2014 | Kevin C Oboyle | Director | Sell | 1,603 | $10.98 | $17,600.94 | |
| 5/28/2014 | Jon Faiz Kayyem | SVP | Sell | 6,000 | $11.06 | $66,360.00 | |
| 5/8/2014 | Richard Slansky | CFO | Sell | 2,302 | $9.26 | $21,316.52 | |
| 4/9/2014 | Hany Massarany | CEO | Sell | 3,985 | $9.87 | $39,331.95 | |
| 3/26/2014 | Jennifer Anne Williams | SVP | Sell | 30,195 | $9.97 | $301,044.15 | |
| 3/5/2014 | Jon Faiz Kayyem | SVP | Sell | 7,355 | $12.46 | $91,643.30 | |
| 1/16/2014 | Jon Faiz Kayyem | SVP | Sell | 50,000 | $14.05 | $702,500.00 | |
| 1/7/2014 | Hany Massarany | CEO | Sell | 4,698 | $13.31 | $62,530.38 | |
| 12/6/2013 | Michael Gleeson | SVP | Sell | 2,211 | $11.14 | $24,630.54 | |
| 12/4/2013 | Hany Massarany | CEO | Sell | 3,968 | $11.14 | $44,203.52 | |
| 10/9/2013 | Hany Massarany | CEO | Sell | 3,925 | $12.05 | $47,296.25 | |
| 10/1/2013 | Jon Faiz Kayyem | SVP | Sell | 6,000 | $12.14 | $72,840.00 | |
| 9/4/2013 | Jeffrey Alan Hawkins | SVP | Sell | 1,890 | $11.60 | $21,924.00 | |
| 9/3/2013 | Hany Massarany | CEO | Sell | 2,354 | $11.60 | $27,306.40 | |
| 9/3/2013 | Jon Faiz Kayyem | SVP | Sell | 1,545 | $11.60 | $17,922.00 | |
| 8/20/2013 | Jon Faiz Kayyem | SVP | Sell | 1,310 | $10.15 | $13,296.50 | |
| 7/1/2013 | Jon Faiz Kayyem | SVP | Sell | 6,000 | $10.40 | $62,400.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for GenMark Diagnostics (NASDAQ:GNMK)
Latest Headlines for GenMark Diagnostics (NASDAQ:GNMK)
| Source: |
|
| Date | Headline |
|---|
 | GenMark Diagnostics, Inc. (NASDAQ:GNMK) Expected to Announce Quarterly Sales of $12.61 Million
www.americanbankingnews.com - July 16 at 8:58 AM |
| Brokerages Expect GenMark Diagnostics, Inc. (GNMK) to Announce -$0.31 EPS
www.americanbankingnews.com - July 14 at 1:24 PM |
| GenMark Diagnostics, Inc. (NASDAQ:GNMK) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 7 at 8:55 AM |
| Research Analysts Offer Predictions for GenMark Diagnostics, Inc.'s FY2018 Earnings (GNMK)
www.americanbankingnews.com - July 3 at 9:41 AM |
 | GenMark Diagnostics (GNMK) Announces CE Mark for ePlex Blood Culture Identification Gram-Positive and Gram-Negative Panels
www.streetinsider.com - June 29 at 11:08 PM |
 | GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Gram-Positive and Gram-Negative Panels
finance.yahoo.com - June 29 at 11:08 PM |
| GenMark Diagnostics (GNMK) Commences $65M Common Stock Offering
www.streetinsider.com - June 14 at 11:56 AM |
| GenMark Diagnostics Prices Upsized Public Offering of Common Stock
finance.yahoo.com - June 13 at 10:21 PM |
| Needham & Company LLC Raises GenMark Diagnostics, Inc. (GNMK) Price Target to $17.00
www.americanbankingnews.com - June 13 at 8:14 AM |
| GenMark Receives FDA 510(k) Market Clearance for Its ePlex® Instrument and Respiratory Pathogen Panel
finance.yahoo.com - June 12 at 6:17 PM |
| GenMark Diagnostics, Inc. – Value Analysis (NASDAQ:GNMK) : June 12, 2017
finance.yahoo.com - June 12 at 6:17 PM |
| GenMark Diagnostics Commences Public Offering of Common Stock
finance.yahoo.com - June 12 at 6:17 PM |
| GenMark Diagnostics, Inc. (GNMK) Given Buy Rating at Canaccord Genuity
www.americanbankingnews.com - June 12 at 1:48 PM |
| GenMark Diagnostics, Inc. (GNMK) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 12 at 10:58 AM |
| GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : June 9, 2017
finance.yahoo.com - June 9 at 10:10 AM |
| ValuEngine Upgrades GenMark Diagnostics, Inc (GNMK) to "Hold"
www.americanbankingnews.com - June 4 at 2:32 PM |
| GenMark Diagnostics to Present at the 2017 William Blair Growth Stock Conference
finance.yahoo.com - May 31 at 10:26 PM |
| GenMark Diagnostics, Inc (GNMK) Expected to Post Quarterly Sales of $13.98 Million
www.americanbankingnews.com - May 27 at 9:48 AM |
| GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : May 26, 2017
finance.yahoo.com - May 26 at 6:08 PM |
| GenMark Diagnostics, Inc (GNMK) CFO Scott Mendel Sells 2,135 Shares
www.americanbankingnews.com - May 23 at 8:35 PM |
| Michael Gleeson Sells 1,916 Shares of GenMark Diagnostics, Inc (GNMK) Stock
www.americanbankingnews.com - May 23 at 8:34 PM |
| Insider Selling: GenMark Diagnostics, Inc (GNMK) Insider Sells 8,239 Shares of Stock
www.americanbankingnews.com - May 23 at 8:18 PM |
| Scott Mendel Sells 1,268 Shares of GenMark Diagnostics, Inc (GNMK) Stock
www.americanbankingnews.com - May 17 at 11:32 PM |
| GenMark Diagnostics, Inc (GNMK) Receives Buy Rating from BTIG Research
www.americanbankingnews.com - May 17 at 1:32 PM |
| GenMark Diagnostics, Inc (GNMK) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 16 at 8:42 AM |
| GenMark Diagnostics, Inc (GNMK) Short Interest Update
www.americanbankingnews.com - May 11 at 9:06 AM |
| GenMark Diagnostics, Inc (GNMK) Insider Hany Massarany Sells 1,571 Shares
www.americanbankingnews.com - May 6 at 12:58 AM |
| GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : May 5, 2017
finance.yahoo.com - May 5 at 10:41 PM |
| ETFs with exposure to GenMark Diagnostics, Inc. : May 5, 2017
finance.yahoo.com - May 5 at 5:39 PM |
| Insider Selling: GenMark Diagnostics, Inc (GNMK) Insider Sells 1,571 Shares of Stock
www.americanbankingnews.com - May 4 at 10:42 PM |
| GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 4 at 12:07 PM |
| GenMark Diagnostics, Inc (GNMK) Releases Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 4 at 12:22 AM |
| GenMark Diagnostics, Inc (GNMK) Issues Earnings Results
www.americanbankingnews.com - May 3 at 10:28 PM |
| GenMark Diagnostics to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 3 at 10:16 PM |
| GenMark Diagnostics (GNMK) Getting Somewhat Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - May 3 at 9:34 PM |
| GenMark Diagnostics, Inc (GNMK) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - May 3 at 3:17 PM |
| Edited Transcript of GNMK earnings conference call or presentation 2-May-17 8:30pm GMT
finance.yahoo.com - May 3 at 8:47 AM |
| Investor Network: GenMark Diagnostics, Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 7:31 PM |
| GenMark Diagnostics reports 1Q loss
finance.yahoo.com - May 2 at 7:31 PM |
| GenMark Diagnostics (GNMK) Earns Daily Media Sentiment Rating of 0.26
www.americanbankingnews.com - April 30 at 1:53 PM |
| GenMark Diagnostics (GNMK) Earns Media Sentiment Score of 0.12
www.americanbankingnews.com - April 27 at 11:50 PM |
| GenMark Diagnostics (GNMK) Getting Positive Press Coverage, Study Shows
www.americanbankingnews.com - April 24 at 4:52 PM |
| GenMark Diagnostics (GNMK) Given Media Impact Score of 0.39
www.americanbankingnews.com - April 21 at 8:46 PM |
 | GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Fungal Pathogen Panel
www.businesswire.com - April 21 at 5:27 PM |
| GenMark Diagnostics, Inc (GNMK) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 21 at 9:23 AM |
| CORRECTING and REPLACING GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Fungal Pathogen Panel
finance.yahoo.com - April 20 at 5:35 PM |
| GenMark Diagnostics Schedules First Quarter 2017 Financial Results Conference Call for May 2, 2017
finance.yahoo.com - April 19 at 11:50 AM |
| GenMark Diagnostics (GNMK) Earns Daily News Impact Rating of -0.12
www.americanbankingnews.com - April 18 at 1:56 PM |
| ETFs with exposure to GenMark Diagnostics, Inc. : April 13, 2017
finance.yahoo.com - April 13 at 5:18 PM |
| GenMark Diagnostics, Inc (GNMK) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 11 at 11:33 PM |
GenMark Diagnostics (GNMK) Chart for Monday, July, 24, 2017
